Disease Group Leader, GU Medical Oncology @BIDMChealth @DanaFarber_GU, Asst Prof @harvardmed, dad, cyclist, Far Side superfan
Massachusetts, USA
Joined January 2015
- Tweets1.2K
- Following739
- Followers954
- Likes381
David Einstein retweeted
The MSKCC Genitourinary Oncology Service is looking for a motivated, patient-centered, clinical investigator with a focus on urothelial cancer. Join a great team focused on eradicating GU cancers!
msk.wd108.myworkdayjobs.com/…
Super insightful piece. With Daniel Sentana and @CaPsurvivorship, we’ve had similar debates re the meaning of healthcare contact days in advanced prostate cancer.
"Ultimately, time is the most precious thing any person has—never more so than after a cancer diagnosis—and protecting how it is spent is a goal worth our shared effort."
Our piece - The commodification of Time Toxicity In Oncology
ascopubs.org/doi/10.1200/JCO…
David Einstein retweeted
Fair points, nicely laid out.
With ADT, my top Q is: Does giving ADT now buy this patient sufficiently lower risk of something worse down the road?
If 6m ADT with MDT only delays need for ADT in the future, that’s not good enough. Needs to ⬇️death or ⬆️treatment-free survival.
David Einstein retweeted
🌟 Past and current @BIDMC_HOFellows presented at #ASCOQLTY26, including work led by @JRusheen implementing a BILH-wide tobacco screening and cessation referral program.
David Einstein retweeted
Updated LUNAR analysis out in @EUplatinum. Now with a median follow-up of 32 months, exploratory analyses confirm the addition of 177Lu-PNT2002 to SBRT improves polymetastatic PFS (6 or more new lesion), castrate disease-free survival, and CT-based PFS (i.e., conventional MFS) authors.elsevier.com/sd/arti…
Congrats!! What about AI for ebikes?
Incredibly proud of this partnership between @Google & our faculty, led by Drs. @AdamRodmanMD, Mark Cohen, Jacob Koshy & Peter Brodeur, to test AMIE, Google’s patient facing conversational AI tool, in the first-of-its-kind, real world clinical study with primary care patients! ⬇️
David Einstein retweeted
We're hiring! The @WilmotCancer GU Medical Oncology program at the @UofR is recruiting genitourinary medical oncologists to join our team.
Why Wilmot?
• A rapidly growing NCI-designated cancer center
• The largest clinical trials program in the region
• Rochester and the Finger Lakes: a region known for an exceptional quality of life
Whether you're an established GU oncologist or finishing fellowship and looking for a place to build your career, we'd love to talk.
Message me directly to learn more, and please share with any colleagues who might be a good fit.
#GUOncology #MedicalOncology #HemOnc #Oncology #Hiring
I’m playing in this fun concert next Friday night: Star Wars, Harry Potter, Les Mis, and more! bostonwagnersociety.org/even…
Now available online! vimeo.com/1225068609?share=c…
David Einstein retweeted
Very excited to welcome four outstanding new faculty to the Lank Center for Genitourinary Oncology @DanaFarber
1) Dr. Nazli Dizman @NazliDizman
2) Dr. Brian Russell @brian_russell39
3) Dr. Hamid Emamekhoo @HamidEmamekhoo
4) Pr. Neeraj Agarwal @neerajaiims
They bring complementary expertise spanning clinical investigation, microbiome science, informatics, quality improvement, education, and GU oncology.
Hamid and Neeraj will also take on important broader institutional leadership roles @DanaFarber and @Harvard Cancer Consortium @df_hcc
We are fortunate to have them—and the @DanaFarber_GU and our patients are in very good hands.
Welcome to @CityOfBoston and @DanaFarber!
Many reasons to be cautious about overtreating BCR…
Here’s how @LaurenOLoughli3 presents this complex discussion to pts:
urotoday.com/video-lectures/…
An argument not to EMBARK on systemic therapy for biochemical recurrence of prostate cancer tau.amegroups.org/article/vi… @EAntonarakis
David Einstein retweeted
With befitting fanfare, we bid farewell to these 8 exceptional @BIDMC_HOFellows who have lived, learned, and cared with the integrity, intellect, and generosity of spirit that define our community. We are so proud to be your colleagues and friends! @rushadpatell
David Einstein retweeted
🎉 Congratulations to our outstanding class of outgoing @BIDMC_HOFellows! We are grateful to have mentored you along your professional journeys and so excited for your exciting futures ahead.
With befitting fanfare, we bid farewell to these 8 exceptional @BIDMC_HOFellows who have lived, learned, and cared with the integrity, intellect, and generosity of spirit that define our community. We are so proud to be your colleagues and friends! @rushadpatell
Congrats to the graduating GU (and all) @BIDMC_HOFellows of 2026! And a clean sweep of the nursing/admin awards for our stellar GU team!
David Einstein retweeted
📢 PALLIATIVE CARE IS SIMPLY GOOD CARE AIMED TO MEET PEOPLE’S NEEDS!
It is part of routine care.
It is NOT mutually exclusive with active treatment.
There is never “nothing we can do” - there is always something we can do to help.
It’s not always “find a new shiny drug.”
#ASCO26
David Einstein retweeted
SENTRY is an IIT, phase II, for localized HR (N0 on PSMA). RT+18m ADT vs RT+6m ADT/ARPI.
RSI MRI and PSMA PET required. Focal boost required if feasible.
MDT alone encouraged for oligomet recurrence.
Primary endpoint: FFS; “failure” of initial Rx plan = salvage ADT or CRPC.
David Einstein retweeted
@DanaFarber and @DanaFarber_GU 's very own @AtishChoudhury presents compelling de-intensification data from A-DREAM/A032101 in mHSPC: 41% of favorable responders remained treatment-free with testosterone recovery 18 months after ADT + ARPI interruption, supporting treatment holidays as a promising strategy in selected pts.
#ASCO26 #ProstateCancer
@OncoAlert @ASCO @OncBrothers
David Einstein retweeted
Congratulations to our incredible GI Medical Oncologist @BrunoBockorny on his work on KMT2C mutation in GI malignancies! @BIDMC_CancerCtr #ASCO2026
